The future of electroencephalography (EEG) monitoring may soon look like a strand of hair. In place of the traditional metal electrodes, a web of wires and sticky adhesives, a team of researchers from Penn State created a hairlike device for long-term, non-invasive monitoring of the brain’s electrical activity. The lightweight and flexible electrode attaches directly to the scalp and delivers stable, high-quality recordings of the brain’s signals.

The research team, led by Professor Minee L. Choi from the Department of Brain and Cognitive Sciences, in collaboration with University College London (UCL) and the Francis Crick Institute, discovered that the RNA-editing enzyme ADAR1 plays an important role in controlling immune responses in astrocytes, glial cells that trigger protective reactions in the brain, and demonstrated that this mechanism is critically involved in the progression of Parkinson’s disease.

FaceHeart Vitals™ is a video-based, contactless vital sign measurement SDK that can be integrated into devices such as smartphones seamlessly, providing heart rate, respiration rate, blood pressure and other vital sign readings in 50 seconds.

Could it be possible to diagnose Parkinson’s disease with the help of a simple retinal exam? The idea should be seriously considered, according to a study published in the May issue of Neurobiology of Disease by researchers from Université Laval who discovered that the retina of people with Parkinson’s disease responds differently to light stimuli than that of healthy people.

In Nature Communications, the laboratory of Professor Jan Terje Andersen and collaborators report on a novel vaccine technology platform, in which the subunit antigen is genetically fused to albumin.

A discovery by scientists at Henry Ford Health + Michigan State University Health Sciences could pave the way for new breakthroughs in detecting and treating the disease. Their findings were recently published in Nature Communications.

During the early teen years, many new strains of C. acnes colonize the skin on our faces. This could be an optimal time for probiotic treatment.

Edwards Lifesciences (NYSE: EW) announced today that it received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.